Managing Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies

Bridgitte Shen Lee, 1 Alan G Kabat, 2 Jason Bacharach, 3 Paul Karpecki, 4 Jodi Luchs 5 1Vision Optique, Houston, TX, USA; 2Pennsylvania College of Optometry, Elkins Park, PA, USA; 3Florida Eye Microsurgical Institute, Boynton Beach, FL, USA; 4Kentucky Eye Institute, Lexington, KY, USA; 5Florida...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shen Lee B, Kabat AG, Bacharach J, Karpecki P, Luchs J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	otx-101 dry eye disease nanomicelles drug delivery Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/930ce1eb19a84a50ac5965224f9eab61
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:930ce1eb19a84a50ac5965224f9eab61
record_format	dspace
spelling	oai:doaj.org-article:930ce1eb19a84a50ac5965224f9eab612021-12-02T06:24:46ZManaging Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies1177-5483https://doaj.org/article/930ce1eb19a84a50ac5965224f9eab612020-01-01T00:00:00Zhttps://www.dovepress.com/managing-dry-eye-disease-and-facilitating-realistic-patient-expectatio-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Bridgitte Shen Lee, 1 Alan G Kabat, 2 Jason Bacharach, 3 Paul Karpecki, 4 Jodi Luchs 5 1Vision Optique, Houston, TX, USA; 2Pennsylvania College of Optometry, Elkins Park, PA, USA; 3Florida Eye Microsurgical Institute, Boynton Beach, FL, USA; 4Kentucky Eye Institute, Lexington, KY, USA; 5Florida Vision Institute, West Palm Beach, FL, USACorrespondence: Bridgitte Shen LeeVision Optique, 5158 Buffalo Speedway, Houston, TX 77005, USATel +1 713-838-2020Email bshenlee@gmail.comAbstract: Dry eye disease (DED) is a multifactorial disease of the ocular surface characterized by loss of homeostasis of the tear film and accompanied by ocular signs and symptoms such as corneal and conjunctival damage, patient discomfort, and visual disturbance. The prevalence of DED ranges from 5%− 33%. Patients with DED may have a reduced quality of life due to their discomfort and visual disturbances. The multifactorial nature of DED requires a multi-targeted treatment approach to address the signs and symptoms. Treatment for DED should follow a step-wise approach beginning with education, dietary modification, and lid and lash hygiene, and progressing to pharmacologic and nonpharmacologic interventions. Ocular lubricants, a mainstay of DED therapy, provide temporary symptomatic relief for the patient, but do not address the underlying pathophysiology. Some currently available pharmacologic treatments that address the underlying pathophysiology of DED may have a delay of 3− 6 months in the onset of therapeutic effect; however, these treatment options may also have tolerability issues. These challenges highlight the need for newer pharmacologic treatments with an earlier onset of observable clinical effect and the potential for improved tolerability profile. Patient education is vital to DED management and should convey the complex and chronic nature of DED. It is important for the eye care practitioner to set realistic expectations with the patient when managing DED to help improve treatment success. This helps the patient understand the need for ongoing treatment and that results will likely not be seen immediately. This review covers the current management of DED, focusing on pharmacologic management, and offers recommendations for the practitioner to help facilitate realistic patient expectations for the treatment of DED.Keywords: OTX-101, dry eye disease, nanomicelles, drug deliveryShen Lee BKabat AGBacharach JKarpecki PLuchs JDove Medical Pressarticleotx-101dry eye diseasenanomicellesdrug deliveryOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 14, Pp 119-126 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	otx-101 dry eye disease nanomicelles drug delivery Ophthalmology RE1-994
spellingShingle	otx-101 dry eye disease nanomicelles drug delivery Ophthalmology RE1-994 Shen Lee B Kabat AG Bacharach J Karpecki P Luchs J Managing Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies
description	Bridgitte Shen Lee, 1 Alan G Kabat, 2 Jason Bacharach, 3 Paul Karpecki, 4 Jodi Luchs 5 1Vision Optique, Houston, TX, USA; 2Pennsylvania College of Optometry, Elkins Park, PA, USA; 3Florida Eye Microsurgical Institute, Boynton Beach, FL, USA; 4Kentucky Eye Institute, Lexington, KY, USA; 5Florida Vision Institute, West Palm Beach, FL, USACorrespondence: Bridgitte Shen LeeVision Optique, 5158 Buffalo Speedway, Houston, TX 77005, USATel +1 713-838-2020Email bshenlee@gmail.comAbstract: Dry eye disease (DED) is a multifactorial disease of the ocular surface characterized by loss of homeostasis of the tear film and accompanied by ocular signs and symptoms such as corneal and conjunctival damage, patient discomfort, and visual disturbance. The prevalence of DED ranges from 5%− 33%. Patients with DED may have a reduced quality of life due to their discomfort and visual disturbances. The multifactorial nature of DED requires a multi-targeted treatment approach to address the signs and symptoms. Treatment for DED should follow a step-wise approach beginning with education, dietary modification, and lid and lash hygiene, and progressing to pharmacologic and nonpharmacologic interventions. Ocular lubricants, a mainstay of DED therapy, provide temporary symptomatic relief for the patient, but do not address the underlying pathophysiology. Some currently available pharmacologic treatments that address the underlying pathophysiology of DED may have a delay of 3− 6 months in the onset of therapeutic effect; however, these treatment options may also have tolerability issues. These challenges highlight the need for newer pharmacologic treatments with an earlier onset of observable clinical effect and the potential for improved tolerability profile. Patient education is vital to DED management and should convey the complex and chronic nature of DED. It is important for the eye care practitioner to set realistic expectations with the patient when managing DED to help improve treatment success. This helps the patient understand the need for ongoing treatment and that results will likely not be seen immediately. This review covers the current management of DED, focusing on pharmacologic management, and offers recommendations for the practitioner to help facilitate realistic patient expectations for the treatment of DED.Keywords: OTX-101, dry eye disease, nanomicelles, drug delivery
format	article
author	Shen Lee B Kabat AG Bacharach J Karpecki P Luchs J
author_facet	Shen Lee B Kabat AG Bacharach J Karpecki P Luchs J
author_sort	Shen Lee B
title	Managing Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies
title_short	Managing Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies
title_full	Managing Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies
title_fullStr	Managing Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies
title_full_unstemmed	Managing Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies
title_sort	managing dry eye disease and facilitating realistic patient expectations: a review and appraisal of current therapies
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/930ce1eb19a84a50ac5965224f9eab61
work_keys_str_mv	AT shenleeb managingdryeyediseaseandfacilitatingrealisticpatientexpectationsareviewandappraisalofcurrenttherapies AT kabatag managingdryeyediseaseandfacilitatingrealisticpatientexpectationsareviewandappraisalofcurrenttherapies AT bacharachj managingdryeyediseaseandfacilitatingrealisticpatientexpectationsareviewandappraisalofcurrenttherapies AT karpeckip managingdryeyediseaseandfacilitatingrealisticpatientexpectationsareviewandappraisalofcurrenttherapies AT luchsj managingdryeyediseaseandfacilitatingrealisticpatientexpectationsareviewandappraisalofcurrenttherapies
_version_	1718399950058946560

Managing Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies

Ejemplares similares